Ascendis Pharma A/S has received FDA accelerated approval for YUVIWEL® (navepegritide; TransCon® CNP), marking a major milestone in the treatment of achondroplasia.
YUVIWEL becomes the first and only once-weekly therapy approved to increase linear growth in children aged 2 years and older with achondroplasia who have open growth plates.
Achondroplasia is a rare genetic skeletal dysplasia driven by overactive FGFR3 signaling, which disrupts normal bone growth and contributes to lifelong complications.
YUVIWEL stands out for two reasons:
Approval was granted under the FDA’s Accelerated Approval Program, based on improvements in annualized growth velocity (AGV). Continued approval may depend on confirmation of clinical benefit in follow-on trials.
YUVIWEL is a prodrug of C-type natriuretic peptide (CNP) designed using Ascendis’ TransCon technology.
Its mechanism:
This pharmacologic profile differentiates it from daily treatment options.
The FDA’s decision was based on a comprehensive clinical package that included:
The pivotal ApproaCH trial, with data published in JAMA Pediatrics, demonstrated meaningful improvements in growth velocity.
According to Carlos A. Bacino of Baylor College of Medicine, YUVIWEL provides physicians with a once-weekly option supported by strong efficacy and tolerability data.
The approval was welcomed by Little People of America, which emphasized the importance of keeping patient voices central in decisions around new medical options.
Ascendis highlighted that patient advocacy input directly shaped development priorities, focusing on outcomes that matter most to individuals and families living with achondroplasia.
YUVIWEL’s safety profile includes:
As with all accelerated approvals, ongoing studies will further characterize long-term benefit and safety.
Ascendis expects to make YUVIWEL available in the United States in early Q2 2026, supported by its Ascendis Signature Access Program (A.S.A.P.), which will offer:
In addition, the FDA issued Ascendis a Rare Pediatric Disease Priority Review Voucher (PRV), providing priority review for a future drug application.
With FDA accelerated approval, YUVIWEL introduces a new, less burdensome treatment paradigm for children with achondroplasia.
Once-weekly dosing, sustained CNP exposure, and a growing clinical data package position YUVIWEL as a potentially transformative option, pending confirmatory evidence, for a community with long-standing unmet needs.